Bernstein Downgrades SentinelOne Despite Price Target Hike
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Bernstein's Peter Weed cut S to Market Perform from Outperform today — while simultaneously raising his price target to $25 from $21. The mixed signal lands as short sellers quietly build positions and the broader cybersecurity sector rallies hard.
The Downgrade That Isn't Quite Bearish
The Bernstein move is the headline. A downgrade paired with a 19% target increase is unusual. It signals Weed sees the stock as fairly valued after a sharp run — not deteriorating fundamentally. S gained 19.2% over the past week alone, tracking peers like RPD (+18.0%), NTSK (+19.6%), and CRWD (+16.2%).
The analyst consensus still sits at "buy," with 16 buy ratings against 15 holds. The mean price target is $24.38 — just above Tuesday's close of $23.17. That tight gap between price and consensus target helps explain Bernstein's caution.
Wedbush assumed coverage on September 11 with an Outperform and a $25 target, pulling in the opposite direction.
Short Interest Climbs Into the Rally
Short sellers added positions through the surge. SI rose 13% over the past week to 5.9% of free float. That is the highest level in recent sessions, though still within a moderate range for a growth cybersecurity name.
The borrow market tells a calmer story. Cost to borrow sits at 0.24% — down sharply from 0.44% a month ago. Availability is exceptionally loose at 1,762% — meaning roughly 18 shares are available to borrow for every one already lent out. There is no meaningful squeeze pressure here. Shorts are adding into a stock with a deep, liquid lending pool.
Insider Sales Add a Layer of Caution
The 90-day net insider position is -$10.8 million. CEO Tomer Weingarten sold 114,890 shares on September 11 at $19.89 for approximately $2.3 million. He also sold 38,759 shares on September 8 at $19.79 — that second transaction carries no 10b5-1 plan, meaning it was a discretionary sale. CFO Sonalee Elizabeth Parekh and Chief Legal Officer Keenan Conder also sold in the same window. The CLO's September 8 sale was similarly not under a pre-arranged plan.
Discretionary insider sales into a strong run are worth noting. They don't override analyst views, but they add texture.
Data Summary
- Bernstein action: Downgrade to Market Perform; PT raised to $25 from $21
- Consensus: 16 buy, 15 hold; mean PT $24.38
- 1-week price change: +19.2%
- SI % of free float: 5.9%, up 13% week-on-week
- Cost to borrow: 0.24%, down ~43% over one month
- Borrow availability: 1,762% — very loose
- 90-day net insider value: -$10.8M; two discretionary sales on Sept. 8
- Next earnings: December 4, 2026
Stocks in this article
See the live data behind this article on ORTEX.
Open S on ORTEX →How this article was generated
- Generated
- 17 Sept 2026, 12:04
- Data as of
- 17 Sept 2026, 12:03
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.